IMBECU   20882
INSTITUTO DE MEDICINA Y BIOLOGIA EXPERIMENTAL DE CUYO
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Prognostic value of BRCA1 in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
Autor/es:
SOTTILE FLEURY ML; DAGUERRE P.; IBARRA J; GÓMEZ LC; LEUZZI M; VARGAS ROIG LM; REDONDO AL; GAGO FE
Lugar:
San Luis
Reunión:
Congreso; XXXVII Reunión Científica Anual de la Sociedad de Biología de Cuyo; 2019
Institución organizadora:
Sociedad de Biología de Cuyo
Resumen:
Breast cancer is the leading cause of cancer death in women in Argentina. Anthracycline-based regimens represent the major chemotherapeutic agents used in breast cancer treatment. As DNA-damaging agents, anthracyclines induce DNA single and double strands breaks which are repaired by homologous recombination (HR) mechanism. The expression of DNA repair proteins varies among breast tumors and the DNA repair status can affect the chemotherapy response. The aim of our work was to determine the predictive/prognostic value of HR proteins CtIP and BRCA1 in breast cancer patients treated with neoadjuvant doxorubicin (DOX) or epirubicin (EPI) monochemotherapy. BRCA1 and CtIP expression was evaluated by immunohistochemistry in pre- and post-chemotherapy tumor biopsies (n=32) and compared with the tumor response and the patients? follow-up. BRCA1 expression increased in tumor cells after DOX/EPI administration whereas CtIP expression significantly decreased after chemotherapy. No associations were found between DNA repair proteins expression and the clinical and pathological response to neoadjuvant chemotherapy. However, BRCA1 expression (˃10% of tumor cells) in the post-chemotherapy biopsies was associated with better DFS and OS (P